Clinical Trials Logo

Clinical Trial Summary

ASK120067 Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03502850
Study type Interventional
Source Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Contact Tingting Song
Phone 025-85100150
Email songtingting@ask-pharm.com
Status Recruiting
Phase Phase 1/Phase 2
Start date November 30, 2017
Completion date August 2021

See also
  Status Clinical Trial Phase
Completed NCT03037086 - Asia PDL1 Study Among NSCLC Patients N/A
Recruiting NCT05662670 - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03274479 - PBF-1129 in Patients With NSCLC Phase 1
Not yet recruiting NCT05990127 - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer Phase 3
Active, not recruiting NCT03969823 - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC N/A
Completed NCT04207775 - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed NCT05631678 - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole Phase 1
Not yet recruiting NCT06461156 - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1
Active, not recruiting NCT04143607 - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC Phase 3
Completed NCT03414814 - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation Phase 2
Completed NCT04360915 - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects Phase 1